Veracyte will present new results that showcase the ability of the Envisia Genomic Classifier to provide reliable data that helps physicians diagnose interstitial lung disease (ILD) — including idiopathic pulmonary fibrosis (IPF) — at CHEST 2018 meeting.
Veracyte also will present new results about the capability of the Percepta Bronchial Genomic Classifier to reduce the need for unnecessary invasive procedures while diagnosing lung cancer.
CHEST 2018, the annual meeting of the American College of Chest Physicians, is being held Oct. 6-10 in San Antonio, Texas.
Lung cancer and IPF/ILD can be difficult to diagnose without the use of invasive procedures. Consequently, patients have to endure risky, expensive, and potentially unnecessary diagnostic surgery, as well as delayed and possibly inappropriate treatment.
The Envisia Genomic Classifier was developed to help physicians more easily differentiate IPF from other ILDs, so that they can design optimal patient treatment plans to help improve outcomes and reduce risk.
The Envisia classifier works by combining gene expression data, using a technique called RNA sequencing, and an artificial intelligence technique, called machine learning. Those are used to detect a genomic pattern of usual interstitial pneumonia (UIP), whose presence is a requisite for an IPF diagnosis.
The current gold standard for detecting UIP is histopathology (microscopic examination of tissue), as obtained through a surgical biopsy. The Envisia test has been shown to detect UIP at levels similar to those detected by histopathology, and without the need for an invasive surgical procedure.
In turn, the Percepta Bronchial Genomic Classifier also uses advanced genomic and machine learning technology, but to help physicians determine which patients are at a lower risk for lung cancer, and should instead be monitored with CT scans as opposed to more invasive diagnostic procedures. The test is designed to detect molecular changes in the lungs’ airways.
“These new study data supporting the Percepta and Envisia classifiers add to the growing body of evidence demonstrating that our genomic tests enable more confident diagnoses of lung cancer and ILDs, including IPF,” Bonnie Anderson, Veracyte’s chairman and CEO, said in a press release.
“We are committed to ensuring that physicians who treat these diseases feel confident that the Percepta and Envisia classifiers will give them reliable answers to help inform accurate and timely diagnoses, without the need for surgery,” Anderson said.
At CHEST 2018, David A. Lynch, MD, from the National Jewish Health, will present data about the Envisia classifier (Oct. 8, 7:45 a.m. CDT) in an oral presentation titled, “Molecular diagnosis of usual interstitial pneumonia (UIP) from transbronchial biopsy is accurate in subjects without definite or probable UIP on CT.”
Data on the Percepta classifier will be presented by Hans J. Lee, MD, from the Johns Hopkins University School of Medicine (Oct. 9, 2:45 p.m. CDT) in an oral presentation titled, “Clinical Utility of a Bronchial Genomic Classifier for Lung Cancer Detection: Results From a Multicenter Prospective Registry”.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?